This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Early-stage cognitive impairment in Parkinson’s disease and the influence of dopamine replacement therapy


Miah, I. P., Olde Dubbelink, K. T., Stoffers, D., Deijen, J. B., Berendse, H. W.


European Journal Of Neurology: The Official Journal Of The European Federation Of Neurological Societies, Volume: 19, No.: 3, Pages.: 510-516

Year of Publication



Background and Purpose: The aim of this study was to establish the cognitive profile of newly diagnosed untreated (de novo) patients with Parkinson’s disease (PD) and more advanced, treated patients, and to determine the effects of dopamine (DA) replacement therapy.; Methods: A cohort of 23 de novo patients, 55 mild to moderately advanced, medicated PD patients and 21 healthy controls participated. Cognitive tests included the Cambridge Examination for Mental Disorders and a battery of neuropsychological tests taken from the Cambridge Neuropsychological Test Automated Battery and the Vienna Test System.; Results: De novo patients with PD were more impaired in working memory strategy use than healthy controls and treated patients with PD. Furthermore, the generation of random motor behaviour was more impaired in both de novo and treated PD patients than in healthy controls. Correlation analysis revealed that in treated patients with PD, ascending doses of dopaminergic medication were associated with poorer performance on a pattern recognition task.; Conclusion: Selective impairments in strategy use and the generation of random motor behaviour are a very early feature of PD and might be of predictive value in further frontal cognitive deterioration. Furthermore, DA replacement therapy seems to improve frontal lobe function (strategy use) and worsen temporal lobe function (visual memory).; © 2011 The Author(s). European Journal of Neurology © 2011 EFNS.

Bibtex Citation

@article{Miah_2011, doi = {10.1111/j.1468-1331.2011.03578.x}, url = {}, year = 2011, month = {oct}, publisher = {Wiley-Blackwell}, volume = {19}, number = {3}, pages = {510--516}, author = {I. P. Miah and K. T. Olde Dubbelink and D. Stoffers and J. B. Deijen and H. W. Berendse}, title = {Early-stage cognitive impairment in Parkinson's disease and the influence of dopamine replacement therapy}, journal = {European Journal of Neurology} }


administration & dosage, antiparkinson agents, cognition disorders, complications, da, dopamine, dopamine agents, drug therapy, etiology, female, humans, male, middle aged, neuropsychological tests, parkinson disease, prevention & control, psychology, replacement, therapy

Countries of Study


Types of Dementia

Parkinson’s Dementia

Types of Study

Non randomised controlled trial

Type of Outcomes

Cognition, Physical Health

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions